
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is an attractive investment opportunity due to their strong pipeline of clinical-stage product candidates, which have shown positive results in recent trials. Their targeted approach to oncology treatments, integrating small molecule drug discovery with biomarker identification, indicates a high potential for success in developing precision medicine for select patient populations. With multiple successful trials and an expanding pipeline, the company is poised for growth and has a promising outlook for the future.
Bears say
IDEAYA Biosciences is a precision medicine oncology company with a focus on synthetic lethality. However, their limited details on safety and tolerability for their clinical-stage product candidates, combined with previously reported high rates of Grade 3+ TEAEs and TRAE discontinuations, raise concerns about the potential challenges in the development of their core assets. Additionally, their valuation of $54/share is based on optimistic assumptions, which may not be achievable given these potential issues.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares